The company has launched enterprise AI services and a voice agent and is considering a rebrand. JPMorgan believes the new businesses will take time to significantly drive growth, while the core business’s ability to withstand AI disruption remains key to its valuation.
Intel’s third-quarter profit beat expectations, but a fourth-quarter decline in the PC business and the shutdown of its Israeli factory weighed on guidance; capacity expansion will add to cash flow pressure in 2027.
Equinix’s annualized gross new bookings exceeded 500 million dollars for the first time in the third quarter, and pricing on new deals rose 12% year over year. JPMorgan sees room for price increases over multiple years as contracts renew, while its model shows expansion spending will continue to depress free cash flow.
AWS growth rose to 39% in the third quarter but still fell short of buy-side expectations. Amazon is optimistic about growth over the next two years and is preparing to increase investment. JPMorgan expects rising capital spending to weigh significantly on free cash flow in 2027.
Shell hopes to use higher oil prices to strengthen its balance sheet; meanwhile, rising freight costs are squeezing realized refining margins, and the cash contribution from Pearl GTL’s restart is subject to timing constraints.
In the quarter ended September 2026, SanDisk’s data-center revenue rose 61% sequentially, driving results and next-quarter guidance above market expectations. Morgan Stanley believes tight NAND supply and buybacks will support earnings, but consumer revenue has already declined sequentially.
Morgan Stanley expects Palantir’s third-quarter revenue to exceed the midpoint of company guidance by 5%–6%, but slowing US commercial customer growth, expectations for the fourth quarter and a high valuation limit the room for optimism.
AWS grew 39% year over year in the third quarter, below Morgan Stanley’s expectations. Rising capital spending and backlog support the long-term growth outlook, while cash flow and the costs of the satellite business remain under pressure.
Amazon and Intel’s cloud and server businesses are still growing, but cash investment, capacity and PC inventory reductions have changed near-term earnings expectations; SNDK and TWLO also face tests of their growth mix and margins.
Xi’an Xice Testing’s third-quarter revenue rose 42.43% year on year and its loss narrowed. The company is entering commercial space through its testing and electrical assembly capabilities and has taken a stake in a joint venture to expand into satellite design, launch and in-orbit delivery.
Quyu Jianpi Tea has entered the public consultation stage for OTC conversion, and existing out-of-hospital channels could help expand its sales. SIF001, a drug in which the company holds an indirect stake, has entered Phase II clinical trials in the United States, but its long-term sales potential still depends on research and development progress.
Management expects memory gross margin to continue rising in the fourth quarter, but global DRAM capacity is tight, and memory shipments next year are expected to be similar to this year’s. NOR Flash customers are seeking long-term agreements, and newly reserved capacity is expected to come online gradually from the second half of next year.
Indices climbed after a lower open, with PCB stocks leading the tech recovery and capital returning to robotics after divergent trading. Cailian Press is watching whether short-term sentiment can improve and how revenue is progressing at robotics supply-chain companies.
In the first three quarters of 2026, Yifeng Pharmacy’s revenue rose 5.49% year on year, while net profit attributable to shareholders rose 10.36%. Guojin Securities believes industry store closures and improving same-store growth at the company could support further growth.
Third-quarter revenue in 2026 rose just 1.8% year on year, but gross margin and recurring net margin increased quarter on quarter. Bernstein sees quarterly fluctuations in revenue recognition, lowered its full-year revenue forecast and maintained its Outperform rating.
A Bernstein expert interview suggests that Trop2 ADCs combined with immunotherapy could change first-line treatment for some patients with non-small cell lung cancer, but overall survival benefits, toxicity management and global trials will determine the scope of their use.
A decline in low-end products lifted net revenue per hectolitre, but failed to offset higher unit costs and expenses. Bernstein expects aluminium price pressure to persist through 2027 and slightly raised its H-share target price.
UMC’s third-quarter results and fourth-quarter guidance both missed expectations. The company expects average selling prices to rise 10% in 2027 and plans to have AI-related capacity in place by 2030. Bernstein is concerned that depreciation and material costs will limit gross margin improvement.
Third-quarter revenue was about 17% below market consensus, and gross margin also fell due to the customer mix. Bernstein values the growth in orders and improving supply of domestically produced components, but its model also shows rising working-capital and capital-expenditure pressures over the next two years.
SoC test equipment drove quarterly revenue above market consensus, prompting the company to accelerate capacity expansion and raise its full-year targets; meanwhile, the depletion of lower-cost inventory and rising component prices will weigh on second-half operating margins.
